The U.S. Department of Health and Human Services (HHS) has announced a significant investment of $590 million to Moderna, Inc. to expedite the development and clinical trials of a vaccine targeting the avian influenza virus. This funding aims to enhance preparedness against potential outbreaks and ensure rapid response capabilities in the face of emerging infectious diseases.